News
For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis Applies to Market Bronchitol for Cystic Fibrosis in Europe
Pharmaxis has filed an application with the European Medicines Agency (EMeA) to market Bronchitol in Europe for the treatment of cystic fibrosis.
Read full media release - pdf
Pharmaxis Commences Pivotal Bronchiectasis Study and Aligns Global Registration Strategy
Pharmaxis today announced that it has commenced screening patients in its pivotal twelve month Phase 3 trial of Bronchitol for bronchiectasis and has moved to streamline its global regulatory strategy for this indication. As part of this strategy, Pharmaxis has voluntarily withdrawn its marketing application to the Therapeutic Goods Administration (TGA) in Australia for the use of Bronchitol to treat bronchiectasis.
Read full media release - pdf
Chairman's Address to AGM
Chairman's Address to the 2009 Annual General Meeting held on 21 October 2009
Read full media release - pdf